NCT05243979

Brief Summary

To evaluate the relation between thyroid, parathyroid hormones and estimated glomerular filtration rate in chronic kidney disease .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 8, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 17, 2022

Completed
12 days until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2023

Completed
Last Updated

February 22, 2022

Status Verified

February 1, 2022

Enrollment Period

1 year

First QC Date

February 8, 2022

Last Update Submit

February 19, 2022

Conditions

ThyroidParathyroid DiseasesCKD

Keywords

ThyroidParathyroid DiseasesCKD

Outcome Measures

Primary Outcomes (1)

  • The Relation between thyroid , parathyroid hormones and estimated glomerular filtration rate in chronic kidney disease patients in Assiut

    To evaluate the relation between thyroid, parathyroid hormones and estimated glomerular filtration rate in chronic kidney disease different stages

    Baseline

Study Arms (2)

Group (A)

40 patients with CKD (1-3) not on renal replacement therapy.

Radiation: DEXA scan

Group (B)

40 persons with normal kidney function and GFR ( control ).

Interventions

DEXA scanRADIATION

bone study

Group (A)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Assuit University Hospital -Internal medicine department (Inpatient and outpatient settings).

You may qualify if:

  • \. CKD patients 2. Age (18-80 years) 3. Diabetic nephropathy 4. Hypertensive nephropathy 5. Chronic pyelonephritis 6. Obstructive nephropathy 7. Polycystic kidney 8. Gout nephropathy 9. Nephrosclerosis

You may not qualify if:

  • \. Patients underage of 18 and above 80 2. Patients with history of thyroidectomy and parathyroidectomy 3. Patients with history of thyroid and parathyroid disease before diagnosis of CKD 4. Malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (8)

  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. No abstract available.

    PMID: 32998798BACKGROUND

  • Laible M, Horstmann S, Rizos T, Rauch G, Zorn M, Veltkamp R. Prevalence of renal dysfunction in ischaemic stroke and transient ischaemic attack patients with or without atrial fibrillation. Eur J Neurol. 2015 Jan;22(1):64-9, e4-5. doi: 10.1111/ene.12528. Epub 2014 Aug 4.

    PMID: 25091540BACKGROUND

  • Banerjee D, Jha V. Vitamin D and Cardiovascular Complications of CKD: What's Next? Clin J Am Soc Nephrol. 2019 Jun 7;14(6):932-934. doi: 10.2215/CJN.12581018. Epub 2019 May 7. No abstract available.

    PMID: 31064752BACKGROUND

  • Ammirati AL. Chronic Kidney Disease. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s03-s09. doi: 10.1590/1806-9282.66.S1.3.

    PMID: 31939529BACKGROUND

  • Kuczera P, Adamczak M, Wiecek A. Endocrine Abnormalities in Patients with Chronic Kidney Disease. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(2):109-18. doi: 10.1515/prilozi-2015-0059.

    PMID: 27442377BACKGROUND

  • Peters J, Roumeliotis S, Mertens PR, Liakopoulos V. Thyroid hormone status in patients with impaired kidney function. Int Urol Nephrol. 2021 Nov;53(11):2349-2358. doi: 10.1007/s11255-021-02800-2. Epub 2021 Mar 8.

    PMID: 33682051BACKGROUND

  • Guo Y, Wang Q, Lu C, Fan P, Li J, Luo X, Chen D. New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study. BMC Endocr Disord. 2020 Jan 8;20(1):5. doi: 10.1186/s12902-019-0487-8.

    PMID: 31914999BACKGROUND

  • Habas E Sr, Eledrisi M, Khan F, Elzouki AY. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus. 2021 Jul 14;13(7):e16388. doi: 10.7759/cureus.16388. eCollection 2021 Jul.

    PMID: 34408941BACKGROUND

MeSH Terms

Conditions

Thyroid DiseasesParathyroid Diseases

Interventions

Absorptiometry, Photon

Condition Hierarchy (Ancestors)

Endocrine System Diseases

Intervention Hierarchy (Ancestors)

RadiographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDensitometryPhotometryChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Sara Magdy

    Assiut University

    STUDY CHAIR

  • Hanan Mahmoud

    Assiut University

    STUDY CHAIR

  • Nashwa Mostafa

    Assiut University

    STUDY CHAIR

Central Study Contacts

Sara Magdy

CONTACT

01098777997dr.sara54.sm@gmail.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

February 8, 2022

First Posted

February 17, 2022

Study Start

March 1, 2022

Primary Completion

March 1, 2023

Study Completion

April 1, 2023

Last Updated

February 22, 2022

Record last verified: 2022-02